Abstract: Pediatric uveitis differs from adult-onset uveitis and is a topic of special interest because of its diagnostic and therapeutic challenges. Children with uveitis are often asymptomatic and the uveitis is often chronic, persistent, recurrent, and resistant to conventional treatment. Anterior uveitis is the most common type of uveitis in children; the prevalence of intermediate, posterior, and panuveitis varies geographically and among ethnic groups. Regarding etiology, most cases of pediatric uveitis are idiopathic but can be due to systemic inflammatory disorders, infections, or a manifestation of masquerade syndrome. Ocular complications include cataracts, hypotony or glaucoma, band keratopathy, synechiae formation, macular edema, optic disc edema, choroidal neovascular membranes, and retinal detachment. These complications are often severe, leading to irreversible structural damage and significant visual disability due to delayed presentation and diagnosis, persistent chronic inflammation from suboptimal treatment, topical and systemic corticosteroid dependence, and delayed initiation of systemic diseasemodifying agents. Treatment for noninfectious uveitis is a stepwise approach starting with corticosteroids. Immunomodulatory therapy should be initiated in cases where quiescence cannot be achieved without steroid dependence. Patients should be monitored regularly for complications of uveitis along with systemic and ocular adverse effects from treatments. The goals are to achieve steroid-free durable remission, to reduce the risk of sight-threatening complications from the uncontrolled ocular inflammation, and to avoid the impact of lifelong burden of visual loss on the child and their family. Multidisciplinary management will ensure holistic care of affected children and improve the support for their families.
A lthough pediatric uveitis accounts for only 5-10% of all uveitis, 1 it is a topic of special interest because of its diagnostic and therapeutic challenges. Children may be asymptomatic despite severe inflammation and often present late. The uveitis is more commonly bilateral, [1] [2] [3] [4] [5] chronic, recurrent, and resistant to treatment; the risk of developing vision-threatening complications is high. 3 Other considerations include difficulties in comprehensive eye examination in a young child, the risk of amblyopia, and lifelong burden of visual loss with its impact on the child and their family.
ANATOMICAL CLASSIFICATION OF UVEITIS
The Standardisation of Uveitis Nomenclature (SUN) criteria are used to define the anatomical location and onset, duration, course of uveitis, and grading of disease activity for reproducible assessment and monitoring of disease. 6, 7 The course of uveitis is defined as acute (sudden onset, lasting for less than 3 months), recurrent (repetitive episodes separated by quiescent periods lasting more than 3 months), and chronic (persistent uveitis for more than 3 months). However, the onset may not be clearly defined in children due to the lack of symptoms. Anatomically, it is classified as anterior (iris and ciliary body), intermediate (vitreous and pars plana), posterior (choroid and/or retina) uveitis, or panuveitis (anterior, intermediate, and posterior uveitis). 6, 7 Uveitis can be granulomatous or nongranulomatous.
Anterior uveitis is consistently the most common form in children globally. 8 A Japanese study reported 56.3% of patients with anterior uveitis, 28.1% with panuveitis, 15.6% with posterior uveitis, and no patients with intermediate uveitis. 2 In series from tertiary centers in North America and Europe, anterior uveitis is the most common (35-50%), followed by posterior uveitis (15-25%), intermediate uveitis (10-20%) and panuveitis (10-20%) . 8 A recent study in the United States 5 showed slightly higher prevalence of anterior uveitis (61.9%) and lower prevalence of posterior uveitis (3.2%) compared with previous studies from Western countries (30.4-56 .9% for anterior uveitis; 6.31-24.9% for posterior uveitis). 3, 4, 9 This trend was attributed to the higher prevalence of juvenile idiopathic arthritis (JIA)-associated uveitis and the decreased proportion of posterior uveitis due to the lower prevalence of toxocariasis and toxoplasmosis in Western countries. 9 Intermediate uveitis is more common in North America 8 and is infrequently seen in Japan. 2 
ETIOLOGY OF UVEITIS
Uveitis may be isolated or a manifestation of systemic disease. The majority of pediatric uveitis, especially intermediate and anterior uveitis, is idiopathic. 2, 4, 5, 9 The remaining cases can be broadly classified into infectious (viral, bacterial, parasitic, and less commonly, fungal) and noninfectious etiologies.
Autoimmune diseases constitute a large proportion of the noninfectious causes. This includes diseases seen in adults such as Vogt-Koyanagi-Harada (VKH) disease and sarcoidosis, along with those specific to the pediatric population such as JIA, Kawasaki syndrome, and tubulointerstitial nephritis-uveitis syndrome.
9 Sporadic early-onset sarcoidosis (onset before age 5) and familial autosomal dominant hereditary Blau syndrome are both characterized by the triad of granulomatous dermatitis, polyarthritis, and uveitis. Masquerade syndrome can present as noninfectious uveitis. It is important to exclude retinoblastoma and underlying hematological malignancies.
The etiology of nonidiopathic cases varies greatly depending on the ethnic and geographic distribution. Uveitis was associated with a systemic disease in 39.86% of patients in an American study, of which JIA was the most common (34.96%). 5 In contrast, only 10.9% of Japanese patients had systemic associations, of which the most common was Behçet disease; none of the patients had JIA. 2 Uveitis associated with JIA is the most common cause of pediatric anterior uveitis in North America and Europe, 1, 4, 8, 9 likely due to the higher prevalence of JIA, particularly oligoarticular JIA, the most common type of JIA 10 that is also associated with a higher risk of anterior uveitis.
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SPECIFIC UVEITIS ENTITIES Entities Presenting Predominantly as Anterior Uveitis
JIA-Associated Uveitis
Uveitis is one of the most severe and frequent extraarticular manifestations of JIA. The disease activity reduces around 9 years of age and peaks around puberty. 12 Uveitis may precede the diagnosis of arthritis in 3-7% of cases. 13 Uveitis associated with JIA most commonly manifests as chronic anterior uveitis, 14 which is often clinically silent. As such, the screening guidelines by the Royal College of Ophthalmologists and British Society for Paediatric and Adolescent Rheumatology recommend that the first ophthalmological assessment for children diagnosed with JIA takes place within 6 weeks of referral. 15 Risk factors for chronic anterior uveitis include patients with a younger age (less than 6 years) at onset of arthritis, female sex, oligoarticular disease, and positive antinuclear antibodies. 13, [16] [17] [18] In contrast, males, those with HLA-B27 positivity, and enthesitisrelated JIA are more prone to developing acute or recurrent anterior uveitis. 13, [16] [17] [18] These patients are generally older and symptomatic with eye pain, redness, photophobia, and headache.
The main predictor of severe uveitis with complications is a short time interval from the onset of arthritis to the onset of uveitis 19 ; other risk factors include being male, a young age at onset of uveitis, and synechiae at presentation. 20, 21 In almost half of children with JIA-associated uveitis, the activity persists into adulthood. 22 
Entities Presenting With Predominantly Intermediate Uveitis
Pars Planitis
Pars planitis refers to idiopathic intermediate uveitis with snowbank or snowball formation, 7 where other causes such as sarcoidosis, acute disseminated encephalomyelitis, tuberculosis, and Lyme disease have been excluded. Although associated systemic disease is rare in children, idiopathic intermediate uveitis has been reported in association with HLA-DR2 and HLA-DR15. 23 Intermediate uveitis typically affects children and adolescents. As inflammation occurs mainly over the vitreous base, pars plana, and peripheral retina, the vitreous base should be examined carefully with scleral indentation. Signs include mildto-moderate anterior segment inflammation, diffuse vitreous cells and haze, snowballs, and/or snowbanks. The most frequent complications are optic disc edema and cystoid macular edema (CME), the leading cause of visual morbidity. 24 Other complications include band keratopathy, peripheral corneal endotheliopathy, and posterior synechiae; vitreous hemorrhage associated with snowbanks or secondary to neovascularization of the optic disc; and inferior peripheral retinoschisis, which develops almost exclusively in children. 25 Children with disease onset at 7 years of age or younger are at higher risk of complications and have poorer visual prognosis than older children. 26 
Ocular Sarcoidosis
Sarcoidosis is a chronic systemic granulomatous disease of unknown etiology. Pediatric sarcoidosis is relatively rare and mostly affects children from 8 to 15 years old. Children under 5 years old present with a triad of uveitis (most commonly limited to the anterior segment), skin lesions, and arthritis mainly affecting the knee and wrist joints. Older children present similarly to adults; they may have pulmonary involvement and both anterior and posterior segment inflammation.
Ocular sarcoidosis most commonly manifests as chronic granulomatous anterior uveitis with mutton-fat keratic precipitates and iris nodules. Intermediate uveitis with moderate-tosevere vitreous inflammation, snowball, and snowbanking of the pars plana region with inflammatory exudates can be seen. Multiple choroidal granuloma or sarcoid tubercles and periphlebitis with candle wax drippings may be seen in the posterior segment.
The diagnosis can be made, at least in older children, based on typical signs of ocular disease and laboratory abnormalities. 27 However, serum angiotensin-converting enzyme levels tend to be higher in children and may be misleading when used for diagnosis. 28 A definitive diagnosis is made with a biopsy specimen showing noncaseating granulomatous inflammation.
Entities Presenting With Predominantly Posterior Uveitis or Panuveitis
Toxoplasmosis
Toxoplasmosis is one of the most common causes of posterior uveitis in children 29 due to the global prevalence of the protozoan Toxoplasma gondii. It may be transmitted from cats to humans directly via exposure to cat litter boxes or indirectly via ingestion of raw or undercooked meats. Ocular toxoplasmosis has significant geographic variation. South American children with congenital toxoplasmosis are at much higher risk of ocular lesions, develop retinochoroiditis earlier, have larger and more numerous lesions that are more likely to affect the retina responsible for central vision, and have an earlier recurrence of retinochoroiditis compared with European children. 30, 31 Congenital toxoplasmosis occurs via transplacental transmission of T. gondii; the risk of transmission is higher when the mother acquires the disease later during the pregnancy. Disease acquired during early pregnancy results in more severe and systemic outcomes, presenting with the classic triad of retinochoroiditis, cerebral calcifications, and seizures. The neonate may be premature, small for gestational age, have persistent jaundice, and cerebrospinal fluid pleocytosis. Other reported ocular features include microphthalmos, cataract, and strabismus. 32 Optic nerve atrophy is common in severe congenital toxoplasmosis and is associated with severe visual impairment. 33 Although children infected during the third trimester often have minimal or no symptoms, 80% develop ocular sequelae during the second or third decade of life, 34 presumably when the tissue cysts rupture and release bradyzoites and tachyzoites into the retina.
The hallmark of active ocular toxoplasmosis is focal necrotizing retinochoroiditis, typically seen as a circular or ovalshaped, yellowish-white lesion in the posterior pole. Anterior layers of the retina are affected first, with secondary involvement of the choroid. The retinochoroiditis is usually accompanied by severe vitritis overlying the involved area, resulting in the classic "headlight in the fog" appearance and reduced visual acuity. Ocular toxoplasmosis more commonly results from reactivation of congenital disease, whereby new active satellite lesions appear adjacent to an atrophic scar with hyperpigmented borders. Absence of scarring suggests acquired disease. There may be associated neuroretinitis or papillitis. Anterior chamber spillover inflammation is common in severe cases as granulomatous anterior uveitis and posterior synechiae. Intraocular pressure (IOP) is often elevated. Ocular toxoplasmosis may be complicated by choroidal neovascularization. Fortunately, more than 90% of affected children have normal vision in their better eye; bilateral blindness is uncommon. 35 In an older child with visual complaints and a typical ocular toxoplasmosis lesion, the diagnosis can be confirmed by the presence of T. gondii immunoglobulin G (IgG) serum antibodies. T. gondii DNA or antibodies may be detected on polymerase chain reaction (PCR) of the aqueous humor. 36 Congenital toxoplasmosis is suspected when seroconversion occurs in a pregnant woman and is confirmed by amniotic fluid PCR or neonatal serodiagnosis (Toxoplasma-specific IgG, IgM, and IgA serum antibodies). 37 Cerebrospinal fluid analysis should include Toxoplasma-specific IgG and IgM and examination for T. gondii tachyzoites.
Treatment is aimed at preventing multiplication of protozoa. Small peripheral lesions may not require treatment. The most commonly used treatment regime is pyrimethamine and sulfadiazine, both of which inhibit DNA synthesis; folic acid supplementation is required. Other options include clindamycin (effective against the cyst form) and azithromycin (effective on both tachyzoites and tissue dormant cysts). 38 The combination of trimethoprim and sulfamethoxazole is effective in preventing recurrence of ocular toxoplasmosis. 39 
Vogt-Koyanagi-Harada Disease
Childhood VKH disease is relatively uncommon. 40 It occurs more commonly in people with greater skin pigmentation such as Asians, Asian Indians, Native Americans, Hispanics, [41] [42] [43] and those of certain genetic predispositions like Middle Eastern heritage. Japan is the most affected country where VKH disease represents 10.1% of all uveitis cases. 41 Vogt-Koyanagi-Harada disease has 4 well-recognized stages. The prodromal stage is characterized by flu-like features with neurologic and auditory manifestations. Patients may complain of blurred vision and photophobia.
In the acute uveitic stage, 70% of patients present with bilateral posterior uveitis; the remaining 30% have involvement of the fellow eye after 1-3 days. 43 Clinical signs include thickening of the posterior choroid with optic disc hyperemia or edema, multiple exudative retinal detachments, and mild-to-moderate vitritis. Progression of the inflammation manifests as bilateral granulomatous anterior uveitis and iris nodules. Ear involvement may result in tinnitus, vertigo, and progressive sensorineural hearing loss (especially at high frequencies). Other systemic features include meningoencephalitis and skin involvement (poliosis, vitiligo, and/or alopecia). [44] [45] [46] The convalescent stage may be chronic. Depigmentation begins in the skin as perilimbal vitiligo (Sugiura sign) 47 and subsequently affects the choroid. The fundus develops a "sunset-glow" appearance with foci of hyperpigmentation and Dalen-Fuchs-like nodules appear in the midperiphery of the fundus. 40 In 3 case series of childhood VKH disease, all patients presented with ocular manifestations but had variable systemic features. [44] [45] [46] In a series by Tabbara et al, 44 the majority (69%) had auditory symptoms and none had meningeal manifestations, whereas Rathinam 43 and El-Asrar et al 45, 46 reported meningeal symptoms being more common (53-60.9%) than ear symptoms (13-26.1%).
The chronic stage manifests as a recurrent, mainly anterior granulomatous uveitis. It is during this phase that most visionthreatening complications such as choroidal neovascularization, cataract, glaucoma, and posterior synechiae occur. 43 Disease recurred in 39.1% of patients as anterior uveitis (83.3%) and serous retinal detachment (11.1%) in the series by El-Asrar et al. 46 Significant risk factors for recurrence were initial visual acuity of 20/200 or worse, presence of posterior synechiae at presentation, at least 1 complication, an interval of more than 2 weeks between symptom onset and initiation of treatment, the need for intravenous corticosteroids, and rapid tapering of systemic corticosteroids.
46
Viral Uveitis Including Acute Retinal Necrosis
Although infectious etiologies account for only up to 13% of all childhood uveitis, 48 it is important to recognize these cases as delay in diagnosis can lead to potentially severe and irreversible vision loss, along with involvement of the fellow eye and neurological system. Herpes simplex virus (HSV) and varicella zoster virus (VZV) can present as acute unilateral uveitis or necrotizing retinitis. Cytomegalovirus (CMV) is an important cause of chorioretinitis in immunocompromised children.
Acute retinal necrosis (ARN) is a vaso-occlusive necrotizing retinitis that usually affects healthy, immunocompetent individuals. The contralateral eye is involved in one third of cases and is usually seen within the first 3 months of infection. 49 Causative viruses include HSV type 1 and 2, VZV, and rarely, CMV. Patients typically present with blurred vision, photophobia, floaters, redness, and moderate pain. The diagnostic criteria for ARN were published by the American Uveitis Society. 50 The mild-tomoderate anterior chamber reaction is commonly granulomatous. Vitritis is usually severe and is associated with 1 or more foci of retinal necrosis with discrete borders that progresses rapidly in the absence of treatment. The retinal necrosis starts from the periphery and spreads circumferentially towards the posterior pole. Active vasculitis characterized by vascular sheathing typically affects arteries more than veins. Optic nerve may show optic disc edema. Fundus examination may be challenging in a child, especially in the presence of significant vitritis. It is important to examine the peripheral retina thoroughly so as not to miss these signs.
The diagnosis of viral uveitis can be confirmed with qualitative or quantitative PCR of the aqueous humor to identify the specific virus and quantify the viral load. Cerebrospinal fluid should be sent for PCR in the presence of neurological symptoms.
The aim of medical therapy in ARN is rapid recovery of the disease and prevention of fellow eye involvement. The recommended therapeutic regimen consists of induction with intravenous acyclovir in 3 divided doses for 7-10 days and oral antiviral medication (acyclovir, valacyclovir, or famcyclovir) for up to 6 weeks or more. In ARN caused by CMV or acyclovir-resistant strains of HSV and VZV, ganciclovir can be used with caution; it has greater risks of systemic toxicity. Corticosteroids may reduce the intraocular inflammation and clear the vitreous haze which progresses despite antiviral treatment.
Retinal holes or tears are sequelae of necrosis-induced retinal thinning and atrophy. They start peripherally and typically occur at the junction of normal and affected retina. Retinal holes, combined with subsequent vitreous organization and resultant in traction, lead to the combination of rhegmatogenous and tractional retinal detachment in up to 75% of cases. 51 Prophylactic confluent laser photocoagulation posterior to areas of active retinitis, where retinal holes are likely to develop, can significantly reduce the risk of retinal detachment. 52, 53 Apart from toxoplasmosis and viral uveitis, tuberculosis and parasites like cysticercosis and toxocara can cause uveitis, usually posterior. 4 Tuberculosis causes uveitis by immune phenomenon and is an important cause of uveitis in developing countries. It typically can cause granulomatous anterior uveitis, intermediate uveitis, choroidal tuberculoma, or panuveitis.
Masquerade Syndromes
Masquerade syndromes, though rare, should always be considered in children with uveitis, especially in cases that fail to respond to anti-inflammatory therapy because of the potentially life-threatening nature of the underlying condition. Common causes of masquerade syndromes in children include malignancies (eg, leukemia, retinoblastoma, medulloepithelioma), inherited retinal degenerations (eg, retinitis pigmentosa), and congenital eye disorders (eg, Coats disease). In addition, an intraocular foreign body cannot be excluded even if the child or parents deny recollection of any injury.
Retinoblastoma is the most devastating masquerade. It is the most common intraocular malignancy in childhood, with an incidence from 1 in 17,000 to 34,000 live births. 54 Although retinoblastoma usually presents with leukocoria and strabismus, 55 approximately 0.5-3.0% of children present with anterior and/ or posterior uveitis. 56 The layering of malignant retinoblastoma cells in the anterior chamber may produce a "pseudohypopyon," whereas vitreous seeding from endophytic tumor growth may mimic posterior uveitis. The intraocular tumor may be revealed during examination under general anesthesia. After treatment of the primary tumor, lifelong follow-up for the development of new or recurrent intraocular malignancy along with extraocular malignancy is needed.
Leukemia, the most common childhood malignancy, can present with posterior uveitis. Signs include multiple flame hemorrhages (often with white centers) and retinal infiltrates, which may be neoplastic, infectious, or ischemic. Rarely, leukemia cells can infiltrate the anterior chamber, resulting in a pseudohypopyon; leukemic infiltrates of the iris may also occur. Children with suspected ocular leukemia should be referred to the oncologist immediately.
Juvenile xanthogranuloma is a nonneoplastic histiocytic proliferation seen in children generally younger than 2 years old. Affected children often have yellowish-orange skin lesions. Ocular manifestations include localized or diffuse yellow or creamywhite iris lesions. As these iris lesions have a predisposition to bleeding, the child can present with a spontaneous hyphema and anterior uveitis. Iris lesions often resolve spontaneously, although anti-inflammatory agents may be required in acute episodes.
Scleritis
Scleritis is characterized by edema and cellular infiltration of the scleral and episcleral tissues. Unlike adults in whom diffuse anterior scleritis is the most common subtype, 57, 58 children most commonly present with posterior scleritis. [59] [60] [61] [62] Concurrent anterior scleritis is less common than in adults. 59, 63, 64 Pediatric posterior scleritis is significantly less associated with systemic disease compared with adults [59] [60] [61] [62] [63] [64] but has been reported in association with HLA-B27 in some patients. 59 Most children with posterior scleritis present with pain and have normal or mild blurring of vision. 59 They frequently have bilateral involvement at presentation, concurrent anterior uveitis, and posterior segment signs such as disc swelling and retinal striae or serous retinal detachment. 59 Disc swelling is significantly more common in children. 63, 64 A high level of suspicion and careful fundus examination is important as failure to recognize these posterior segment signs may lead to a missed diagnosis; the child may be incorrectly treated for anterior uveitis instead of scleritis. Posterior scleritis can also pose a diagnostic challenge by presenting with severe inflammation, restricted extraocular muscle movements, and orbital involvement with lid signs in children. 61 Pediatric scleritis may be infectious in etiology. Causative organisms include VZV 65, 66 and Mycobacterium tuberculosis, which is not uncommon in tuberculosis-endemic regions like the Indian subcontinent. 67, 68 A recent case series in an Indian population showed that 15% of pediatric scleritis patients had tuberculous scleritis. 62 Tuberculous scleritis mostly presents as nodular scleritis 57, 68 and may result from either a direct invasion of the M. tuberculosis bacilli or antigen-antibody-mediated inflammation.
COMPLICATIONS
The majority of children with uveitis develop complications 3, 5, 69 ; 34% and 86.3% had at least 1 ocular complication at diagnosis and by 3 years, respectively. 3 Complications occur as a result of delayed diagnosis, chronic disease activity due to suboptimal therapeutic regimen, and may be iatrogenic.
Cataract is a common complication in uveitis 5 due to the intraocular inflammation and use of corticosteroids. Band keratopathy is more common in anterior and intermediate uveitis 3 and can cause visual impairment if involving the visual axis. Synechiae formation is a common complication of anterior uveitis. 4 It can lead to pupil irregularities and, if extensive, secondary angle closure glaucoma. Intermediate uveitis has the highest risk of CME, 3, 70 which can significantly affect vision.
iris bombe as a result of seclusio pupillae, and the use of topical or regional steroids can cause acute severe spikes in IOP and secondary glaucoma. Conversely, ocular hypotony in chronic uveitis may reflect ciliary body shutdown and predicts the development of phthisis, a delayed complication with a poor prognosis. 4 Risk factors for poor visual outcome include male sex, intermediate uveitis, posterior infectious uveitis, and severe disease or complications at presentation. 3, 4, 21, 71 
APPROACH TO MANAGEMENT OF PEDIATRIC UVEITIS
Once an infectious cause and masquerade syndrome have been excluded, uveitis can be treated with a "stepladder approach." The goal is to reduce the risk of sight-threatening complications from chronic or recurrent uncontrolled ocular inflammation and to achieve steroid-free durable remission with quiescence.
Monitoring Children With Uveitis
Children with uveitis should be monitored for disease activity frequently until quiescence is achieved, after which they can be followed up at longer intervals. The visual acuity, IOP, degree of anterior and posterior segment inflammation, and the presence and severity of complications should be documented at each visit. Children on immunosuppressants should be periodically evaluated for specific drug-related adverse effects. Optical coherence tomography of the macula may be more sensitive in detecting edema that may not be clinically apparent. Fluorescein angiography is useful in detecting capillary shutdown and can be considered in suspected vasculitis.
Medical Therapy
Corticosteroids
Topical corticosteroids are the first-line treatment for anterior segment inflammation. As they are generally ineffective in penetrating to the posterior segment, systemic steroids or regional (periocular or subtenon) injections are preferred for the treatment of intermediate or posterior uveitis. Intraocular steroids should be used with caution. General anesthesia may be required for children who require periocular or intraocular steroid injections.
Systemic steroid treatment can be given orally or intravenously when more rapid and potent action is needed.
The use of intravenous high-dose pulse methylprednisolone for 3 consecutive days is safe and effective in controlling aggressive sight-threatening uveitis. A subsequent tapering regimen of low-dose oral steroids is given depending on the severity of the inflammation.
Nonsteroidal Anti-Inflammatory Drugs
When tapering of corticosteroids leads to a recurrence of inflammation, systemic nonsteroidal anti-inflammatory drugs (NSAIDs) may be used, although some find the efficacy to be low. Additionally, NSAIDs are associated with gastrointestinal irritation, renal toxicity, skin rashes, and central nervous system reactions.
Immunomodulatory Therapy
As corticosteroids alone are often insuffient to achieve remission in most children, early initiation of immunomodulatory therapy is therefore key.
Immunosuppressants are broadly divided into biologic and nonbiologic therapy. Methotrexate (MTX) is the first-line immunomodulatory therapy in pediatric uveitis because of its wellestablished safety and efficacy profile in children. 72 Methotrexate is a folic acid analog given subcutaneously once weekly for at least 3 months, with concurrent folic acid replacement. Adverse effects include mouth ulcers and gastrointestinal intolerance; antiemetics can be used in conjunction around the time of MTX injection to relieve these symptoms and improve compliance. The most frequent systemic finding is deranged liver function. If serum aminotransferase levels exceed twice the upper limit of normal on 2 separate occasions, the dose of MTX can be reduced. However, most pediatric rheumatologists would omit MTX for 1-2 weeks until liver function normalizes before restarting MTX, aiming for a dose within the therapeutic range. Other adverse effects of MTX include bone marrow suppression and interstitial pneumonitis, although these have not been reported in children. Screening blood tests should be done monthly for the first 3 months, then 3-monthly while on treatment.
Other nonbiologic immunosuppressive agents include azathioprine, cyclosporine, and mycophenolate mofetil (MMF). Mycophenolate mofetil is in a similar class of antimetabolites as MTX. It is well-tolerated and was used widely before biologic therapy became accepted. However, MMF is less efficacious in uveitis control and is ineffective in treating arthritis in JIA. Azathioprine is less commonly prescribed in children due to gastrointestinal adverse effects. 73 More recently, biologic therapies have been introduced to the treatment options and have become the standard of care in a range of inflammatory diseases including severe ankylosing spondylitis and Crohn disease. Biologics are typically monoclonal antibodies that bind and inhibit proinflammatory cytokines. Of the tumor necrosis factor (TNF)-α inhibitors, infliximab and adalimumab are shown to be the most effective in controlling ocular inflammation 74, 75 ; 87% and 72% of children with autoimmune chronic uveitis refractory to previous disease-modifying drugs responded to adalimumab and infliximab, respectively, with no significant difference between the 2. 74 Adalimumab has the advantages of being administered at home subcutaneously fortnightly, more stable serum concentrations, less risk for anaphylactic reaction, and a more favorable safety profile. Adalimumab combined with MTX is effective in JIA-associated uveitis; a significantly greater proportion of children on adalimumab had a reduced topical glucocorticoid dose or discontinued topical steroids compared with those with placebo. 76 However, they had a higher incidence of adverse events such as minor infections and respiratory and gastrointestinal disorders. Infliximab is given as intravenous infusion every 2-8 weeks; the frequency can be reduced up to 12-weekly in stable cases.
In disease refractory to TNF-α inhibitors, alternative biologic agents such as rituximab, 77 intravenous immunoglobulin, 78 or interferon can be given. However, there is limited data on their use at present and the benefits should be weighed against the risks of potential serious adverse effects such as an increased risk of opportunistic infections, demyelinating disease, and malignancy.
or obscures view of the fundus, precluding monitoring of posterior segment disease. In children with permanent ocular structural damage or where there is no view of the fundus, parents should be counselled on the guarded visual prognosis. Peripheral anterior synechiae should be released before posterior synechiolysis, and any membranes present should also be removed. Intraocular inflammation should be quiescent for at least 3 months before surgery 79 and aggressive courses of pre-and postoperative topical and systemic glucocorticoids may be required to optimize surgical results. An intraocular lens should not be implanted in children younger than 2 years old and is avoided until the disease has been quiescent for 3 months as lens implantation can trigger further inflammation.
Children with glaucoma refractory to medical therapy may benefit from surgical intervention such as goniotomy, insertion of a glaucoma drainage device, or trabeculectomy. 80, 81 However, trabeculectomy often fails within the first few years due to the tendency to scar even when augmented with antimitotics such as 5-fluorouracil or mitomycin-C. At present, the most promising option is the insertion of a glaucoma drainage tube, which provides adequate and reliable long-term IOP control in pediatric secondary glaucoma. Cyclodiode laser should be avoided as it inevitably leads to a uveitic flare.
Band keratopathy involving the visual axis can be treated with excimer laser keratectomy, which can be repeated in recurrence.
Special Considerations in Children
Several issues should also be given consideration in pediatric uveitis. In a young child, reduced visual acuity in unilateral uveitis, whether due to the uncontrolled inflammation or its complications, can lead to amblyopia and lifelong visual disability. It also hinders the child's learning and ability to cope at school. Early and aggressive treatment of the ocular inflammation is therefore important, particularly in children of an amblyogenic age (younger than 7-8 years old). Amblyopia should be treated with occlusion therapy. Once the disease is quiescent, the child should be refracted to determine the best corrected visual acuity and have visual function optimized.
Compliance to treatment can be particularly challenging in children, who often depend on reliable caregiver(s) to administer topical medications regularly and accompany them for follow-up appointments. Administering frequent eyedrops can be difficult in younger children and children who are left responsible for their own eyedrops while at school may not be compliant. This can lead to suboptimal disease control and a more protracted course of inflammation with resultant complications.
The use of topical and periocular corticosteroids is associated with a higher risk of ocular complications in children 82 ; elevated IOP and steroid-induced glaucoma occur much more rapidly in children, may be refractory to treatment, and can persist even after cessation of topical steroids.
As in adults, systemic steroids should only be used for shortterm treatment in children because of significant systemic adverse effects including endocrine (weight gain, adrenal suppression, hypertension, hyperglycemia), gastrointestinal (peptic ulcer, candidiasis), and dermatological (hirsutism, striae, fragile skin, and poor wound healing) changes, along with psychosis and premature osteoporosis. Furthermore, prolonged use of corticosteroids in children can also cause growth retardation due to premature closure of the epiphyseal plates. 83 Corticosteroids can also cause severe ocular adverse effects in children such as cataracts, glaucoma, and even retinal and choroidal emboli. 84 
Multidisciplinary Management
Holistic management of a child with uveitis requires the expertise of a multidisciplinary team. The ophthalmologist should collaborate with the pediatric rheumatologist to ensure that the child is thoroughly evaluated for underlying systemic disease and apppropriately initated on disease-modifying agents. A pediatric uveitis nurse specialist is important to train the patient and family members in the administration of subcutaneous medications. The pharmacist needs to ensure that immunomodulatory therapy is only prescribed if laboratory investigations are within normal limits. Children should also have a specialist pediatric contact lens optometrist to facilitate their postoperative aphakic rehabilitation. As pediatric uveitis can be a chronic sight-threatening condition, a dedicated team of child psychologists will help to support the affected children and their families in coping with the disease and improve compliance to treatment and follow-up.
CONCLUSIONS
In conclusion, pediatric uveitis poses multiple diagnostic and therapeutic challenges. Clinical manifestations of the same disease in children may differ from adults. Early detection and diagnosis along with timely and aggressive treatment to achieve quiescence is paramount to reduce the risk of potentially visually disabling ocular complications. Young children with unilateral uveitis are at particular risk of amblyopia, which should be treated aggressively. Children should be monitored regularly for disease activity and drug-specific adverse effects to guide decisions on therapeutic options. A multidisciplinary team is necessary for the holistic management of children with uveitis to help children and their family cope with the disease and its treatment.
